Skip to content
    Real-World Studies

    Enzalutamide Linked to Longer Time to CRPC Than Apalutamide in mCSPC Cohort

    Ohtani et alJapanese journal of clinical oncology

    Enzalutamide Linked to Longer Time to CRPC Than Apalutamide in mCSPC Cohort
    In a retrospective, multicenter study evaluating 331 consecutive patients with metastatic castration-sensitive prostate cancer (mCSPC), researchers compared real-world effectiveness, treatment modifications, and safety outcomes between first-line apalutamide (n = 208) and enzalutamide (n = 123). Propensity score matching generated 85 balanced pairs (maximum post-match absolute standardized mean difference of 0.073) to analyze the primary endpoint: time to clinically documented castration-resistant prostate cancer (CRPC), defined by prostate-specific antigen (PSA) and/or radiographic progression in a castrate state.
    The primary matching analysis showed that time to clinically documented CRPC was shorter in patients receiving apalutamide compared to enzalutamide (HR 2.13, 95% CI 1.08–4.19; P = .029). These findings were corroborated in sensitivity analyses using stabilized inverse probability of treatment weighting (IPTW) (HR 2.04, 95% CI 1.10–3.75; P = .023) as well as IPTW adjusting for CHAARTED high-volume and LATITUDE high-risk disease burden (HR 2.15, 95% CI 1.13–4.08; P = .020).
    Time to achieve a PSA level <0.1 ng/ml was similar between apalutamide and enzalutamide (HR 1.00, 95% CI 0.66–1.51; P = .996), and overall survival was also comparable (HR 1.30, 95% CI 0.54–3.11; P = .557). Regarding tolerability and treatment delivery, apalutamide therapy was associated with higher frequencies of dose reductions, adverse events, and non-progression-related treatment interruptions or discontinuations. The authors noted that while weighted sensitivity analyses supported the primary association, residual confounding and a limited number of events preclude causal claims.

    Key Takeaways

    • In a propensity score-matched cohort of patients with metastatic castration-sensitive prostate cancer, apalutamide was associated with a shorter time to clinically documented castration-resistant prostate cancer compared to enzalutamide (HR 2.13, 95% CI 1.08–4.19; P = .029), which remained consistent in stabilized IPTW (HR 2.04, 95% CI 1.10–3.75; P = .023) and disease-burden-adjusted IPTW analyses (HR 2.15, 95% CI 1.13–4.08; P = .020).
    • Dose reductions, adverse events, and non-progression-related treatment interruptions or discontinuations occurred more frequently with apalutamide, while overall survival (HR 1.30, 95% CI 0.54–3.11; P = .557) and time to reach a PSA level <0.1 ng/ml (HR 1.00, 95% CI 0.66–1.51; P = .996) were similar between the cohorts.
    Read the original sourceJapanese journal of clinical oncology